HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients [PDF]
BACKGROUND: Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg-positive CHB, and a necessary precursor to HBsAg loss. Biomarkers that predict serological outcomes would be useful.
Yuen, L +16 more
core +1 more source
Background Hepatitis B e antigen (HBeAg) seroclearance has been considered as the treatment endpoint in HBeAg-positive patients with chronic hepatitis B (CHB). Although HBeAg seroclearance has been accomplished, some aspects are yet unclear.
Hyun Woong Lee +5 more
doaj +1 more source
Hepatitis B Virus (HBV) can be transmitted vertically from mother to her baby. Mothers with HBsAg and HBeAg positives have more risk of transmitting HBV to her baby rather than HBsAg positives only. The aim of this study is to determine the proportion of
Melina Rosita Tanadi +2 more
doaj +1 more source
Comparison between HBeAg positive and HBeAg negative subjects with respect to varying HBV DNA levels. [PDF]
Major proportion of HBeAg positive subjects were associated with higher HBV DNA levels compared to HBeAg negative subjects.
Debraj Saha (452305) +10 more
core +1 more source
Prevalence of HBe Ag and LFT Survey in HBsAg Positive Blood Donors in Kerman [PDF]
The hepatitis-B virus (HBV) is one of the most common chronic pathogens in the world. More than 2 billions of world population have been exposed to this virus and 350 millions of them (5% of world population) are chronic carriers of HBV.
M.J Zahedi +4 more
doaj
. Background:. Hepatitis B core-related antigen (HBcrAg) is a promising disease-monitoring marker for chronic hepatitis B (CHB). We investigated correlations between HBcrAg with antiviral efficacy and virological and histological variables. Methods:. One
Jun Li +4 more
doaj +1 more source
Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Treated with Pegylated Interferon α [PDF]
Objective To investigate the efficiency of pegylated interferon α therapy for patients with HBeAg-positive chronic hepatitis B (CHB) and explore whether liver histopathological features and other factors might influence HBeAg seroconversion.
Cheng-liang Zhu +4 more
core +1 more source
AUC of age associated with significant fibrosis in HBeAg-positive and HBeAg-negative PNALT patients. [PDF]
A: AUC of age associated with significant fibrosis in HBeAg-positive PNALT patients. B: AUC of age associated with significant fibrosis in HBeAg-negative PNALT patients.
Li Chen (5749) +4 more
core +1 more source
Levels of 16 identified miRNAs in plasma from HBeAg positive, HBeAg negative, and healthy children. [PDF]
A panel of 16 miRNAs was identified as significantly differentially expressed in plasma from 34 HBeAg positive, 26 HBeAg negative, and 60 healthy children.
Flemming Pociot (42186) +4 more
core +1 more source
The Role of Quantitative HBsAg Levels in Chronic Hepatitis B Infection
Introduction: Chronic hepatitis B (CHB) infection is essential for patient management, including treatment and follow-up. Therefore, quantitative hepatitis B surface antigen (qHBsAg) may help physicians identify the stages of hepatitis B virus (HBV ...
Merve Kılıç Tekin +2 more
doaj +1 more source

